Pratley RE, Catarig AM, Lingvay I, et al. - In this indirect comparison, semaglutide 1.0 mg demonstrated considerably larger HbA1c reductions than dulaglutide 3.0 mg and comparable HbA1c reductions than dulaglutide 4.5 mg. In comparison to dulaglutide 3.0 and 4.5 mg, semaglutide 1.0 mg significantly lowered body weight.

• Clinicians can benefit from information on the efficacy of several glucagon-like peptide-1 receptor agonists. Using published results from the SUSTAIN 7 and AWARD-11 trials, a Bucher indirect comparison was performed to assess efficacy outcomes of semaglutide 1.0 mg vs dulaglutide 3.0 and 4.5 mg.

• Semaglutide 1.0 mg significantly decreased HbA1c compared with dulaglutide 3.0 mg, with an estimated treatment difference (ETD) of −0.24%-points, and comparable declines in HbA1c vs dulaglutide 4.5 mg with an ETD of −0.07%-points.

• With an ETD of −2.65 kg and −1.95 kg, respectively, semaglutide 1.0 mg significantly lowered body weight compared with dulaglutide 3.0 and 4.5 mg.

• The findings of the primary analysis were supported by sensitivity analyses.